The TET2 DNA dioxygenase regulates cell identity and suppresses tumorigenesis by modulating DNA methylation and expression of a large number of genes. How TET2, like most other chromatin-modifying enzymes, is recruited to specific genomic sites is unknown. Here we report that WT1, a sequencespecific transcription factor, is mutated in a mutually exclusive manner with TET2, IDH1, and IDH2 in acute myeloid leukemia (AML). WT1 physically interacts with and recruits TET2 to its target genes to activate their expression. The interaction between WT1 and TET2 is disrupted by multiple AML-derived TET2 mutations. TET2 suppresses leukemia cell proliferation and colony formation in a manner dependent on WT1. These results provide a mechanism for targeting TET2 to a specific DNA sequence in the genome. Our results also provide an explanation for the mutual exclusivity of WT1 and TET2 mutations in AML, and suggest an IDH1/2-TET2-WT1 pathway in suppressing AML.
In Brief
Wang et al. show that WT1 binds directly to TET2 and recruits TET2 to specific genomic sites to regulate WT1-target gene expression. This provides an explanation for the mutual exclusivity of WT1 and TET2 mutations in AML, and suggests an IDH1/2-TET2-WT1 pathway in suppressing AML.
INTRODUCTION
The recently identified ten-eleven translocation (TET) family of proteins, which includes TET1, TET2, and TET3 in mammalian cells, catalyzes three sequential oxidation reactions: converting 5-methylcytosine (5mC) first to 5-hydroxymethylcytosine (5hmC), then to 5-formylcytosine (5fC), and finally to 5-carboxylcytosine (5caC) (He et al., 2011; Ito et al., 2011; Tahiliani et al., 2009) . A subsequent decarboxylation of 5caC, by either a thymine-DNA glycosylase (TDG) or other DNA repair enzymes, could then lead to DNA demethylation (Kohli and Zhang, 2013) . Genetic studies in mutant mice have linked the function of Tet genes to various biological pathways, including zygotic, embryonic, and perinatal development (Dawlaty et al., 2013; Gu et al., 2011) ; differentiation of hematopoietic cells (Ko et al., 2011; Li et al., 2011; Moran-Crusio et al., 2011; Quivoron et al., 2011) ; and induced pluripotent stem cell reprogramming (Costa et al., 2013; Doege et al., 2012) . Such diverse and complex roles are consistent with the binding of TET proteins and the distribution of their catalytic products, 5hmC, 5fC, and 5caC, throughout the genome (Shen et al., 2013; Song et al., 2013; Williams et al., 2011; Wu et al., 2011) . However, it is unclear how TET proteins bind to a specific locus in the genome.
Pathologically, TET2 is frequently mutated in hematopoietic malignancies of both myeloid, in particular acute myeloid leukemia (AML, $15%-20%), and lymphoid lineages, such as angioimmunoblastic T cell lymphoma ($30%-40%) (Delhommeau et al., 2009; Quivoron et al., 2011; Tefferi et al., 2009) . In a subset of AML with wild-type TET2 gene, TET2 enzyme is also catalytically inactivated by D-2-hydroxyglutarate (D-2-HG), an oncometabolite produced by mutated isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) (Chowdhury et al., 2011; Xu et al., 2011) , which occurs in about 20% of AMLs in a mutually exclusive manner with TET2 mutations (Figueroa et al., 2010) . In addition to IDH1, IDH2, and TET2, wilm's tumor gene, WT1, is also frequently mutated in AML (Cancer Genome Atlas Research Network, 2013; Fernandez-Mercado et al., 2012; Liang et al., 2013; Patel et al., 2012; Rocquain et al., 2010; Welch et al., 2012) . WT1 encodes a sequence-specific zincfinger transcription factor involved in the control of organ development and cell differentiation, in particular nephrogenesis and hematopoiesis, and in tumor suppression by regulating the expression of genes involved in different cellular pathways (Huff, 2011; Rivera and Haber, 2005) . In an effort to determine how mutations of WT1 contribute to the development of AML, we noted that the WT1 gene is mutated in AML in a mutually exclusive manner with mutations targeting TET2, IDH1, and IDH2. This pattern of TET2 and WT1 mutation in AML led us to hypothesize that WT1 and TET2 may function in the same pathway in suppressing AML.
RESULTS

WT1, TET2, IDH1
, and IDH2 Are Mutated Mutually Exclusively in AML Somatic mutations targeting IDH1, IDH2, TET2, and WT1 genes occur frequently in AML. We carried out a meta-analysis of a total of 1,057 AML cases where all four genes were sequenced from six separate studies; 303 cases (28.7%) carried mutations targeting at least one of the four genes. As previously reported, the mutations targeting IDH1, IDH2, and TET2 genes occur mutually exclusively (Figueroa et al., 2010) . Notably, the mutations targeting WT1 also occur in a mutually exclusive pattern with those targeting IDH1, IDH2, or TET2 in AML (Figures 1A and 1B) . The mutually exclusive mutation patterns of TET2 and WT1 led us to hypothesize that TET2 and WT1 may function in the same pathway.
TET2 Activates WT1-Target Genes
To determine the functional significance of a mutually exclusive mutation pattern between WT1 and TET2, we first determined whether WT1 and TET2 could affect the expression of each other. It is known that two alternative splice sites result in four major isoforms of WT1: different in the inclusion or exclusion of exon 5 (Ex5+/Ex5À) and three amino acid residues (lysine-threonine-serine, KTS) encoded by exon 9. We found that overexpression of either the (+KTS) or the (ÀKTS) isoform of WT1 led to upregulation of BTRC and TBL1X, two known direct WT1-target genes (Kim et al., 2009 ). In contrast, ectopic expression of either WT1 isoform did not affect the gene expression of TET2 in various cultured cells and vice versa (Figures S1A and S1B available online).
Next, we examined whether TET2, as a broad epigenetic modifier, can modulate WT1-target gene expression. We found that ectopic expression of TET2 in HEK293T cells resulted in the activation of a number of WT1-target genes, including those involved in the Wnt signaling, MAPK signaling, and axon guidance pathway ( Figure 1C ). In addition, we found that the effect of TET2 on activating WT1-target gene expression was dependent on the catalytic activity of TET2, as expression of TET2 catalytic inactive mutant (CM) did not upregulate the expression of WT1-target genes (Figures S1C and S1D). Moreover, co-overexpression of TET2 and WT1 in HEK293T cells synergistically activated the expression of WT1-target genes in a dose-dependent manner (Figures S1E and S1F) . Furthermore, we utilized three short hairpin RNAs (shRNAs) against WT1 to knock down its expression in HEK293T cells ( Figure S1G ). We found that WT1 depletion almost completely abrogated the effect of TET2-mediated activation of WT1-target genes (Figures S1H and S1I), suggesting that the function of TET2 in activating the WT1-target gene is dependent on WT1.
Given that the mutations of WT1 and TET2 occur frequently in AML, we then stably infected human AML HL-60 leukemic cells with retroviral vectors expressing Flag-tagged human full-length TET2 ( Figure 1D ). We found that overexpression of TET2 indeed resulted in the activation of a number of WT1-target genes in HL-60 cells ( Figure 1E ). When we used two different shRNAs against WT1 to deplete its expression in HL-60/TET2-Flag cells, we found that the TET2-induced upregulation of WT1-target gene expression was broadly suppressed by WT1 depletion (Figure 1E) , further supporting the notion that TET2 activates WT1-target genes in a manner dependent on WT1. Notably, when the HL-60/TET2-Flag cells were treated with cell-permeable D-2-HG, which is produced by mutant IDH1 and IDH2 and inhibits the activity of TET enzymes (Xu et al., 2011) , we found that D-2-HG effectively inhibited the effect of TET2 on activating WT1-target gene expression ( Figure 1F ). Moreover, overexpression of wild-type IDH1 in HL-60/TET2-Flag cells activated WT1-target genes, while overexpression of R132C mutant IDH1 inactivated WT1-target genes ( Figures S1J and S1K ). These results further support the notion that the ability of TET2 in activating WT1-target gene expression requires its catalytic activity. It is also consistent with the observation that IDH1, IDH2, TET2, and WT1 genes are mutated in AML in a mutually exclusive manner.
WT1 Physically Binds to TET2
How does TET2 selectively induce expression of WT1-target genes? An appealing model is that the sequence-specific transcription factor WT1 directly binds to TET2 and recruits TET2 to its target genes. To test this hypothesis, we first examined the protein expression of TET2 and WT1 in various cell types. We found that TET2 and WT1 proteins were expressed at a readily detectable level in both HL-60 and KG-1 cells, and were low in HEK239T and HCT116 cells ( Figure S2A ). Next, we determined the endogenous WT1-TET2 association by coupled immunoprecipitation and western blotting (IP-western) in HL-60 and KG-1 cells (Figure 2A ), as well as mouse embryonic stem cells (ESCs) and primary bone marrow cells (BMCs) ( Figure 2B ). This experiment demonstrated that the WT1-TET2 association was readily detected in these four cell lines, suggesting that TET2 and WT1 interact with each other and may be broadly involved in cell regulation beyond hematopoietic lineages.
To further determine the specificity of WT1-TET2 interaction, we ectopically expressed WT1 and the TET2 CD domain (TET2 CD ) that contains both the Cys-rich and the DSBH domains in HCT116 cells. p53, which previously has been shown to bind WT1 (Maheswaran et al., 1993) , and phosphoenolpyruvate carboxykinase were included as positive and negative controls, respectively. This experiment demonstrated the retention of WT1 in the immunoprecipitates of TET2 CD ( Figure 2C ). Furthermore, we found that neither exon 5 nor KTS is required for WT1 to bind with either TET2 CD or full-length TET2 ( Figure S2B ).
Interestingly, the interaction of WT1 is specific to TET2, as evidenced by the observation that neither the (Ex5À/+KTS) nor the (Ex5+/ÀKTS) isoform of WT1 bound to the CD domain of full-length TET1 ( Figures S2C and S2D ).
To define the binding regions between WT1 and TET2, we constructed a series of deletion mutants of both proteins. We found that TET2 binds to the zinc-finger domain (residues 323-449), but not the N-terminal region (residues 1-323) of WT1 ( Figure 2D ). Similar mapping experiments showed that WT1 binds to the CD domain, but not the N-terminal region (residues 1-1127) of TET2 ( Figure 2E ). More importantly, in vitro studies with purified recombinant proteins demonstrated a direct interaction between human WT1 and the CD domain of human TET2 proteins at 1:1 stoichiometry (Figures 2F and 2G Figure 3A) . Notably, the TET2 occupancy on the promoters of WT1-target genes was substantially increased by the coexpression of WT1 in HEK293T cells (Figure 3A) . Hydroxymethylated DNA immunoprecipitation quantitative PCR (hMeDIP-qPCR) analysis was used to track the 5hmC change in the CpG-rich regions of WT1-target gene promoters. We found that coexpression of WT1 and TET2 in HEK293T cells significantly increased 5hmC levels at the promoter regions of BTRC (p = 0.0058), DACT1 (p = 0.0015), and TBL1X (p = 0.0071) ( Figure 3A ). To more accurately quantify the 5hmC and 5mC status at the specific locus within WT1-target gene promoters, we performed glucosylated hydroxymethyl-sensitive qPCR (GluMS-qPCR), which enables a single-base-level determination of the methylation status of CCGG sites in the genome (Xu et al., 2012) . Our data demonstrated that coexpression of WT1 and TET2 in HEK293T cells led to a significant increase in 5hmC and a contaminant decrease in 5mC at particular nucleotide loci (marked as a and b) near TSS of WT1-target genes ( Figure 3B ). Also, we found that, in the promoter regions of WT1-target genes at the sites where 5hmC was increased by TET2 overexpression, ectopic expression of TET2 led to increased levels of the activating histone marker H3K4me3, and that the increase in H3K4me3 was further enhanced by co-overexpressing TET2 with WT1 (Figure S3A) . This is in line with previous studies showing that, in mouse ESCs, gene promoters that are high in 5hmC are enriched in H3K4me3, whereas those enriched in 5mC are depleted of H3K4me3 marks (Ficz et al., 2011) . In contrast to WT1 overexpression, ChIP-qPCR analysis showed that WT1 depletion reduced the TET2 occupancy on the promoters of WT1-target genes to near the background levels in HEK293T cells, but had little effect on TET2 occupancy on the promoters of TMEM116 and CDKL4 ( Figure S3B ), which are known TET2-target genes independent of WT1 (Deplus et al., 2013) .
We then performed ChIP-qPCR analysis to determine the TET2 occupancy on the promoters of WT1-target genes in HL-60 cells. Because of the lack of a TET2 antibody suitable for ChIP analysis of endogenous TET2 occupancy, we generated stable HL-60 cells in which endogenous TET2 was depleted and Flag-TET2 was expressed at a level similar to that of endogenous TET2 protein ( Figure S3C ). Of 17 direct WT1-target genes from five different signaling pathways, we found that WT1 and TET2 bind to all of them at the CpG-rich promoter regions (Figures 3C and S3D) . Moreover, the TET2 occupancy on the promoters of WT1-target genes was significantly decreased to near the background levels by the deletion of endogenous WT1 in these stable HL-60 cells expressing Flag-TET2 ( Figures  3D and S3E ). In addition, we generated stable HL-60 cells with retroviral vectors encoding different shRNAs against WT1 and/or TET2 ( Figure S3F ). We found that knockdown of either WT1 or TET2 led to significantly decreased 5hmC levels and increased 5mC levels at specific nucleotide loci (marked as a and b) in WT1-target genes (i.e., BTRC, DACT1, and TBL1X), but no additive effect was found upon the codepletion of both genes ( Figure 3E ). Accordingly, knockdown of either gene led to downregulation of WT1-target genes, but no additive effect was observed upon the codepletion of both genes ( Figure 3F ). Taken together, these results support the idea that WT1 recruits TET2 to specific genomic sites to regulate gene expression.
TET2 Inhibits Leukemia Cell Proliferation in a WT1-Dependent Manner
To investigate the physiological relevance of the WT1-TET2 interaction, we determined the functional interaction of WT1 and TET2 in controlling leukemia cell proliferation and colony formation. We first examined the effect of ectopically expressed TET2 in the presence and absence of WT1. The expression of TET2 and knockdown efficiency of WT1 were verified by direct immunoblotting ( Figure 1D ). Consistent with tumor suppression function of TET2, in multiple independent experiments, HL-60 cells stably overexpressing Flag-tagged TET2 displayed slower proliferation ( Figure 4A ) and reduced clonogenicity ( Figure 4B ) compared to control cells transfected with the empty vector. Notably, the inhibitory effects of TET2 on leukemic cell proliferation and colony formation were abolished by WT1 knockdown.
We then determined the effect of TET2 and/or WT1 knockdown in HL-60 cells. The knockdown efficiency of TET2 and WT1 was determined by qRT-PCR ( Figure S3F ). We found that the proliferation and colony formation of HL-60 cells were Figure 1 . TET2 Activates WT1-Target Genes (A) Somatic variants in IDH1/2, TET2, and WT1 were identified in a total of 1,057 AML cases, in which 303 cases carried at least one mutation. Data were collected from six different studies (Cancer Genome Atlas Research Network, 2013; Fernandez-Mercado et al., 2012; Liang et al., 2013; Patel et al., 2012; Rocquain et al., 2010; Welch et al., 2012) . stimulated by the depletion of either TET2 or WT1 gene, but not additively by the codepletion of both genes ( Figures 4C and 4D ). We stably infected another human AML cell line, KG-1 cells, with retroviral vectors encoding different shRNAs against WT1 and/or TET2 ( Figure S4A ). In line with the observations in HL-60 cells, knockdown of either TET2 or WT1 gene in KG-1 cells led to the downregulation of WT1-target genes, and again no additive effect was found upon the codepletion of both genes ( Figure S4B Figure S2 .
TET2 or WT1 gene in KG-1 cells, but not additively by the codepletion of both genes ( Figure 4E ). Collectively, these results suggest that TET2 and WT1 function in the same pathway to inhibit leukemia cell proliferation and colony formation.
Multiple Recurrent AML-Derived Mutations in TET2 Disrupt Its WT1 Binding Besides alterations causing truncation, frameshift, insertions, or deletions, a large number of TET2 missense mutations have been reported in AML and only a few of them have been functionally characterized (Ko et al., 2010) . To seek evidence supporting the WT1-mediated TET2 recruitment and explore the pathological significance of their mutually exclusive mutation patterns in AML, we examined the effect on the WT1 binding by a panel of AML-derived mutations targeting the CD domain of TET2 (TET2 CD ) where WT1 binds. Notably, of a total of 28 AML-derived TET2 mutants that we tested, at least seven, D1242V, G1256D, R1302G, A1505T, P1617H, G1861R, and T1884A, severely reduced or completely abolished interaction with Flag-tagged WT1 and their occupancy on WT1-target genes in HEK293T cells ( Figures S5A and S5B) . Importantly, these WT1-binding-defective TET2 mutants were incapable of binding with endogenous WT1 protein in HL-60 cells ( Figure 5A ). None of these seven mutations targets welldefined a-KG-or Fe 2+ -binding residues. To directly examine whether these mutations affect the catalytic activity of TET2, we performed in vitro TET2 activity assay using genomic DNA as the substrate and immunopurified TET2 CD as the enzyme. The wild-type TET2 CD converted all 5mC and 5hmC to 5caC, as seen by the loss of both 5mC and 5hmC after reaction, while the CM TET2 CD , which harbors two mutations disrupting binding with Fe 2+ (He et al., 2011; Ito et al., 2011; Tahiliani et al., 2009 ) and control HA precipitates from cells transfected with the empty vector, had no detectable activity ( Figure 5B ). Of the seven WT1-binding-defective TET2 mutants we characterized, six (D1242V, G1256D, R1302G, A1505T, G1861R, and T1884A) exhibited apparent catalytic activity in converting 5mC and 5hmC to 5caC and one mutant (P1617H) displayed reduced catalytic activity ( Figure 5B ). We also found that AML-derived, WT1-binding-defective mutants, A1505T and P1617H, retained their catalytic activity in oxidizing 5mC, leading to a reduction in 5mC, although less active compared to wild-type TET2 ( Figure S5D ). Furthermore, in vivo TET2 activity assay confirmed that these WT1-binding-defective TET2 mutants retained the catalytic function to produce 5hmC, but their activity was reduced compared to wild-type TET2 (Figure S5E) . In HEK293T cells, overexpression of these WT1-binding-defective TET2 mutants did not increase 5hmC in the CpGrich regions of WT1-target gene promoters (data not shown). As a result, overexpression of these WT1-binding-defective TET2 mutants failed to activate WT1-target genes in HEK293T cells ( Figure S5C ). We conclude that these AML-derived mutations inactivate the function of TET2 mainly by disrupting its binding with WT1 instead of inactivating the catalytic activity of TET2.
To further demonstrate that AML-derived, WT1-bindingdefective TET2 mutants specifically lose their ability to regulate WT1-target genes, we stably infected HL-60 cells with lentiviral vectors encoding the wild-type TET2 CD or three TET2 mutants (A1505T, P1617H, or G1861R). Both wild-type TET2 and its mutants were expressed at a similar level in HL-60 cells, as verified by direct immunoblotting ( Figure 5C ). By performing hMeDIPqPCR analysis, we found that overexpression of wild-type TET2
CD , but not WT1-binding-defective TET2 mutants in HL-60 cells, significantly increased 5hmC levels in the CpG-rich regions of WT1-target gene promoters ( Figure 5D ). Moreover, GluMSqPCR analysis revealed that these WT1-binding-defective TET2 mutants failed to increase 5hmC levels and decrease 5mC levels at specific loci near TSS of WT1-target genes in HL-60 cells ( Figure 5E ). As a result, overexpression of the wildtype TET2 CD , but not AML-derived WT1-binding-defective TET2 mutants, induced the expression of WT1-target genes in HL-60 cells ( Figure 5F ), suggesting a functional dependency of TET2 on binding with WT1 to regulate the expression of WT1-target genes in leukemia cells.
AML-Derived, WT1-Binding-Defective TET2 Mutants Fail to Inhibit Leukemia Cell Proliferation
Finally, we investigated the functional consequence of AMLderived, WT1-binding-defective mutations in TET2. We found that HL-60 cells stably overexpressing the wild-type TET2 CD , but not three TET2 mutants (A1505T, P1617H, or G1861R), displayed decreased proliferation and impaired clonogenicity compared to control cells transfected with the empty vector (Figures 6A and 6B) . Taken together, our results suggest that TET2 negatively regulates leukemia cell proliferation in a WT1-dependent manner and that this tumor suppressor function of TET2 is inactivated by multiple AML-associated TET2 mutations that lost its binding with WT1 ( Figure 6C ).
DISCUSSION
Like most epigenetic modifying enzymes (Smith and Shilatifard, 2010) , the TET DNA dioxygenases do not appear to bind to specific DNA sequences by themselves. Therefore, these general chromatin-modifying enzymes must be recruited to specific targets in the genome by other factors, presumably sequencespecific DNA-binding proteins, to regulate specific cellular processes. At present, little is known about how the recruitment of TET is achieved. In this study, we demonstrate that WT1 binds directly to TET2 and recruits TET2 to specific genomic sites to regulate the expression of WT1-target genes. Our results suggest a mechanism-binding with a sequence-specific transcription factor-by which the TET2 DNA methylhydroxylating enzyme is recruited to specific sequences in the genome, thereby converting 5mC to 5hmC at specific nucleotides in Figure 3 . TET2 Is Recruited by WT1 to Its Target Genes (A) Flag-TET2 was transiently expressed either singularly or with WT1-HA in HEK293T cells. The occupancy of Flag-TET2 at the promoter regions of WT1-target genes was determined by ChIP-qPCR (top), and the 5hmC enrichment at the Flag-TET2-binding sites was determined by hMeDIP-qPCR (bottom). Mouse IgG and rabbit IgG were included as negative controls for ChIP-qPCR and hMeDIP-qPCR, respectively. (B) Flag-tagged wild-type TET2 or its CM of TET2 was transiently overexpressed either singularly or with HA-WT1 in HEK293T cells. The site-specific 5hmC and 5mC levels were determined by using GluMS-qPCR. a and b, MspI/HapII recognition sites of each target gene; arrow, promoter orientation. (C) Stable HL-60 cells with knockdown of endogenous TET2 and put-back of Flag-tagged TET2 were generated as described in Figure S3C . The occupancy of TET2-Flag and endogenous WT1 on the promoter regions of indicated WT1-target genes was determined by ChIP-qPCR. Mouse IgG and rabbit IgG were included as negative controls. Arrow, promoter orientation; green line, CGIs; red dashed line, WT1-binding motif. (D) Stable HL-60 cells in (C) were transduced with retrovirus expressing different shRNAs against WT1. The occupancy of TET2-Flag on the promoter regions of indicated WT1-target genes was determined by ChIP-qPCR. Mouse IgG was included as a negative control. (E) HL-60 cells were transduced with retrovirus expressing different shRNAs against WT1 and/or TET2 as described in Figure S3F . Site-specific levels of 5hmC and 5mC were determined by using GluMS-qPCR. (F) Stable HL-60 cells in (E) were examined for the mRNA expression of indicated WT1-target genes, as determined by quantitative real-time PCR. Shown are average values of triplicated results with SD; *p < 0.05 for the indicated comparison;**p < 0.01 for the indicated comparison; n.s., not significant. See also Figure S3 . specific target genes. This mechanism is supported by three lines of evidence: (1) TET2 physically interacts with WT1; (2) TET2 binds to the promoters of genes that are known to be bound and regulated by WT1 and, importantly, the binding of TET2 to these WT1-target genes depends on the presence of WT1 protein; and (3) the binding of TET2 to WT1-target gene is functional, as seen by the increase of 5hmC and the concomitant decrease of 5mC at the same sites and eventual transcription activation of its target genes. The functional relevance of WT1-recruited TET2 is further supported by the finding that TET2 inhibits leukemia cell proliferation in a WT1-dependent manner.
The pathological significance of WT1-TET2 interaction is evidenced by the finding that this interaction is disrupted by multiple recurrent mutations in TET2 associated with AML, resulting in the loss of ability of TET2 to bind to and activate the expression of WT1-target genes while retaining the catalytic activity of TET2. The WT1-TET2 physical association and dependency of TET2 on WT1 to bind and activate WT1-target genes provide an explanation for the mutually exclusive pattern of mutations of these two genes in AML. Loss-of-function mutations targeting WT1 would have the same consequence as loss-of-function mutations of TET2 in disrupting the regulation of WT1-target genes. There is no advantage for mutating both genes in the same cell for the AML development. Likewise, mutations in IDH1 or IDH2, which produce 2-HG and cause functional inactivation of the TET2 enzyme, would also block the activation of WT1-target genes that are normally activated by the recruitment of TET2, as shown by the inhibition of TET2-mediated WT1-target gene expression in cells treated with D-2-HG ( Figure 1F ) and in cells overexpressing IDH1 R132C mutant ( Figure S1K ). This result provides an explanation for the mutually exclusive mutations among IDH1, IDH2, TET2, and WT1 in AML. Together with the fact that mutations targeting IDH1 and IDH2 share the same biochemical consequences of inactivating their normal activity in producing a-KG and gaining of function in producing 2-HG, indicated, and the ectopically expressed TET2 proteins were immunoprecipitated, followed by western blot to detect endogenous WT1.
(B) For in vitro TET2 catalytic activity assay, genomic DNA was isolated from human monocyte-derived macrophage cells, sonicated, and incubated with immunopurified HA-tagged wild-type and mutant human TET2 at 37 C for 2 hr. After termination of the reaction, a fraction of reaction mixture from each reaction was subjected to dot-blot assay using the antibodies specific for 5mC, 5hmC, 5fC, and 5caC. See Experimental Procedures for more details. our results offer a molecular explanation for the mutually exclusive pattern of mutations targeting these four genes, IDH1/2, TET2, and WT1, in AML. Hence, these results suggest a linear IDH1/2-TET2-WT1 pathway in the suppression of AML ( Figure 6C ). Of note, in addition to AML, both WT1 and TET2 genes were found to be mutated in other types of cancer, such as bladder urothelial carcinoma, breast invasive carcinoma, colorectal adenocarcinoma, kidney renal clear cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, melanoma, and uterine corpus endometrioid carcinoma (Table S2) . Although the size of these tumor samples harboring either TET2 or WT1 mutation is too small for conducting a statistical analysis, we note that mutations targeting TET2 and WT1 genes rarely/never occur in (D-F) Stable HL-60 cells were generated as described in (C). The 5hmC enrichment at TET2-binding sites at the promoter regions of indicated WT1-target genes was determined by hMeDIP-qPCR (D), and rabbit IgG was included as a negative control. Moreover, the site-specific levels of 5hmC and 5mC were determined by using GluMS-qPCR (E), and the mRNA expression of indicated WT1-target genes was determined by quantitative real-time PCR (F). Shown are average values of triplicated results with SD; *p < 0.05; **p < 0.01 for the indicated comparison; n.s., not significant. See also Figure S5 . Table S1 . The shRNA construct was cotransfected with vectors expressing the gag and vsvg genes into HEK293T cells using a two-plasmid packaging system, as previously described (Chen et al., 2013) . Retroviral supernatant was harvested 36 hr after transfection, and mixed with 8 mg/ml polybrene to increase the infection efficiency. Cells were infected with the retrovirus and selected in 1 mg/ml puromycin for 1 week.
To generate stable WT1 and/or TET2 knockdown cell pools in HL-60 and KG-1 cells, shRNA-targeting TET2 gene was constructed in pMKO.1-hyg vector; the shRNA-targeting sequences are shown in Table S1 . The virus was produced as described above. Retroviral supernatant was harvested 36 hr after transfection, and mixed with 8 mg/ml polybrene to increase the infection efficiency. WT1-knocking-down stable cells were infected with the retrovirus and selected in 200 mg/ml hygromycin B for 1 week.
Lentiviral Transduction
For lentivirus production, the HA-tagged TET2 CD -domain-expressing vectors were cotransfected with packaging (psPAX2) and envelope (pMD2.G) vectors into HEK293T cells. Lentivirus was harvested from the supernatant at 24 hr posttransfection, and mixed with 8 mg/ml polybrene to increase the infection efficiency. HL-60 cells were infected with the lentivirus and selected in 1 mg/ml puromycin for 1 week. For the pull-down assay, 400 ng purified recombinant Flag-WT1 (Creative Biomart) and 200 ng recombinant His-Flag-TET2
CD were mixed with nickel beads (QIAGEN) in the wash buffer described above at 4 C overnight. The beads were collected by centrifugation at 2,000 rpm for 3 min at 4 C, and bound proteins were eluted with 300 mM imidazole and subjected to SDS-PAGE. Protein-protein interaction was examined either by western blot with Flag antibody or SYPRO Ruby staining (Invitrogen).
ChIP-qPCR Assays
ChIP-qPCR assays were performed as described previously (Lan et al., 2007) . Briefly, cells were crosslinked with 1% paraformaldehyde and sonicated. Solubilized chromatin was immunoprecipitated with antibodies against WT1, Flag, HA, H3K4me3, or negative control IgG. Antibody-chromatin complexes were pulled down using protein A-sepharose (Millipore), washed, and then eluted. After crosslink reversal and proteinase K treatment, immunoprecipitated DNA was extracted with phenol-chloroform, ethanol precipitated. The DNA fragments were further analyzed by qPCR.
MeDIP-qPCR and hMeDIP-qPCR Analyses
Genomic DNA from cells was prepared using a phenol-chloroform method. The MeDIP and hMeDIP assays were performed as previously described (Ito et al., 2010; Mohn et al., 2009) . Briefly, genomic DNA was denatured and then immunoprecipitated with anti-5mC, anti-5hmC antibody, or IgG control antibody and protein G magnetic Dynabeads (Invitrogen). After washing for three times, beads were treated with proteinase K for 4 hr. DNA was prepared with phenol chloroform and precipitated by using cold ethanol; pulled-down DNA was analyzed by qPCR. All the primers are listed in Table S1 .
GluMS-qPCR Analysis
The 5hmC and 5mC levels in TET2-binding regions containing MspI/HpaII sites were measured by a restriction-enzyme-based assay (EpiMark kit, New England Biolabs) (Kinney et al., 2011) . Genomic DNA was treated with or without T4 Phage b-glucosyltransferase, and then digested by MspI, HpaII, or no enzyme. The MspI-and HpaII-resistant fractions were quantified by qPCR and normalized to the mock digestion. Primers used for GluMS-qPCR are listed in Table S1 .
Statistical Analysis
Statistical analyses were performed with a two-tailed unpaired Student's t test. All data shown represent the results obtained from triplicated independent experiments with SEM (mean ± SD). The values of p < 0.05 were considered statistically significant. were determined by western blot.
SUPPLEMENTAL INFORMATION
Supplemental Table Legends   Table S1 . List of oligonucleotides used in this study
Primers used for retroviral-mediated shRNA against WT1, qRT-PCR, ChIP-qPCR, MeDIP-qPCR, hMeDIP-qPCR, and GluMS-qPCR analyses are listed. Ahn et al., 2014; Cerami et al., 2012; Gao et al., 2013; Hodis et al., 2012; Imielinski et al., 2012; Kandoth et al., 2013; Krauthammer et al., 2012; Lohr et al., 2014; Peifer et al., 2012; Seshagiri et al., 2012) . 
Plasmids
The cDNA encoding full-length human WT1, TET1, TET2, p53 or PEPCK1
were cloned into Flag, HA or GFP-tagged vectors (pcDNA-Flag; pcDNA3-HA; pEGFP-C3). DNA fragments of TET2 catalytic domain (TET2 CD ) and truncated TET2 and WT1 were sub-cloned into pcDNA-Flag, pcDNA3-HA or pEGFP-C3
vectors. Plasmid for shRNA expression with hygromycin resistance (pMKO.1-hyg) was achieved by replacing the puromycin resistance gene with hygromycin resitance gene after introducing BamHI and NotI restriction sites into pMKO.1-puro vector. Flag-tagged human TET2 gene (full length) was subcloned into pQCXIH vector. Flag -tagged human IDH1 gene was subcloned into pBABE vector. HA-tagged CD domain of wild-type TET2 and AML-derived mutants (A1505T, P1617H, and G1861R) were subcloned into lentiviral vector pCDH-Puro. Point mutations were generated as decribed previously (Hartkamp et al., 2010) by site-directed mutagenesis using a QuickChange Site-Directed Mutagenesis kit (Stratagene). All expression constructs were verified by DNA sequencing. heat-inactivated fetal bovine serum (MP Biomedicals), 2 mmol/L L-glutamine, 100 U/mL penicillin/streptomycin.
Cell culture and transfection
HEK293T and
Immunoprecipitation and western blotting
Cells were lysed in ice-cold NP-40 buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% NP-40)] containing protease inhibitor cocktail (Roche).
Immunoprecipitation was carried out either by incubating Flag beads (Sigma) at 4°C with lysate for 3 hrs or by incubating appropriate antibody with cell lysate for 1 hr, followed by incubating with Protein-A beads (Upstate) for another 2 hrs at 4°C before beads were washed for three times with ice-cold NP-40 buffer. Standard western blot protocols were adopted.
RNA isolation and quantitative real-time PCR
Total RNA was isolated from cultured cells using Trizol reagent (Invitrogen) following the manufacturer's instructions. RNA was reverse transcribed with oligo-dT primers and preceded to real-time PCR with gene-specific primers in the presence of SYBR Premix Ex Taq (TaKaRa). β-actin was used as a housekeeping control. Primer sequences were present in the s upplementary Table S1 .
Protein concentration determination
Protein concentrations were determined by the Bradford method (Bradford, 1976 ) using a Bio-Rad Protein Assay Kit (Bio-Rad). SYPRO Ruby staining signal intensity was quantified by generating density histograms for each protein band and then determining the area within the corresponding peak using ImageJ.
Colony formation assay
For colony-formation assay, HL-60 cells were plated (1000 cells per 35mm dish) in methylcellulose-based MethoCult medium (Stem Cell Technologies).
Culture dishes were incubated for 6 days at 37°C in a humid atmosphere with 5% CO 2 . Colonies (>50 μm diameter) were counted using Olympus fluorescence microscope IX18.
In vitro TET2 activity assay
In vitro assay of TET2 catalytic activity was performed following the procedures previously described (Zhang et al., 2014; Zhang et al., 2013) .
Briefly, genomic DNA from monocyte-derived macrophage (MDM) cells was isolated using Wizard Genomic DNA Purification Kit (Promega) following the manufacturer's instructions, sonicated (Covaris Sonicator, 13 min at 4°C) and used as substrate. To prepare the TET enzyme, HA-tagged wild-type and AML-derived TET2-CD mutants were ectopically expressed in HEK293T cells and immunoprecipitated in a NP-40 buffer (50 mmol/L Tris pH 7.5, 150 mmol/L NaCl, 0.3% Nonidet P-40, 1% protease inhibitor (Pierce)) using anti-HA beads (Cell Signaling). HA-TET2 proteins were eluted by HA peptide from the agarose beads and used as the enzyme. To start the reaction, 150 ng sonicated genomic DNA and 200, 400, 800 ng immunopurified proteins were added to a 20 μl reaction buffer containing 50 mM HEPES buffer (pH 8.0), 100 mM ammonium iron (II) sulfate, 1 mM α-ketoglutarate, 2 mM ascorbic acid, 2.5 mM DTT, 100 mM NaCl, 1.2 mM ATP. The reactions were incubated at 37°C
for 1 h with constant shaking on an Eppendorf ThermoMixer (700 r.p.m),
